Clinical Trial Update: A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

View source ↗

Summary

This update reports the completion of a post-marketing surveillance study evaluating Equfina 50 mg tablets in Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Equfina

Snippet

Sponsor: Eisai Korea Inc. | Conditions: Parkinson Disease | Status: COMPLETED